PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1424344
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1424344
The Global Blood Gas Analyzers Market size is estimated to be valued at US$ 2.36 Bn in 2023 and is expected to reach US$ 3.46 Bn by 2030, growing at a Compound Annual Growth Rate (CAGR) of 5.6% from 2023 to 2030.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023/2024: | US$ 2.36 Bn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023/2024 to 2030/2031 CAGR: | 5.60% | 2030/2031 Value Projection: | US$ 3.46 Bn |
Blood gas analyzers play a pivotal role in monitoring critical conditions in patients and have become an indispensable tool for clinicians across emergency rooms and intensive care units. They provide real-time analysis of blood gas, electrolytes, and metabolite parameters including pH, pCO2, pO2, sodium, potassium, ionized calcium, glucose, and lactate directly from blood samples. This helps physicians gain rapid insights into patient's oxygenation, ventilation, and acid-base status, which is vital for timely clinical decision making and management of acute and chronic respiratory diseases, cardiac illnesses, organ transplant, sepsis, trauma, and other critical care conditions. Advancements in miniaturization and portability of devices along with introduction of sophisticated technologies like optical sensing are likely to augment the adoption of blood gas analyzers globally.
The global blood gas analyzers market is primarily driven by the rising geriatric population susceptible to chronic diseases, increasing incidence of respiratory disorders, growing number of ICU admissions worldwide, and increasing number of product launches or approvals.
For instance, in April 2021, LivaNova PLC, a global medical device company, announced that it has received U.S. Food and Drugs Administration (FDA) 510(k) clearance for B-Capta, the in-line, blood-gas monitoring system integrated into the S5 heart-lung machine (HLM). The device is intended to monitor arterial and venous blood gas values even during lengthy and complicated pediatric and adult cardiopulmonary bypass surgeries. B-Capta will now be accessible internationally after receiving CE Mark in May 2020 and completing a successful limited commercial release in Europe.
Blood Gas Analyzers Market Detailed Segmentation: